Ryvu Therapeutics SA · GPW:RVU

Ryvu Therapeutics SA — Investor Presentation (August 2023)

42 slides from Ryvu Therapeutics SA's investor presentation, August 2023

  1. Slide 1: Targeted therapeutics at the forefront of oncology

    Slide 1: Targeted therapeutics at the forefront of oncology

    Targeted therapeutics at the forefront of oncology CORPORATE PRESENTATION August 2023

  2. Slide 2: Note on the presentation and forward-looking statements

    Slide 2: Note on the presentation and forward-looking statements

    Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submit

  3. Slide 3: Ryvu at a glance

    Slide 3: Ryvu at a glance

    Ryvu at a glance Clinical Pipeline Small Molecule Discovery Platform Fully Integrated Across Heme and Solid Tumors Novel Synthetic Lethality Targets Research Organization RVU120 Developing small molecule therapies which address high-value emerging targets >230 employees, including ~150 Wholly owned,

  4. Slide 4: Ryvu's corporate development and share performance

    Slide 4: Ryvu's corporate development and share performance

    Ryvu’s corporate development and share performance 2007-2014 2019 2019-2022 SEL24 RVU120 Partnerships and Financing 2007: Selvita, a hybrid model Corporate spin-out of Selvita biotech company, with joint • Successfully completed • Preliminary positive • Immune modulation research collaboration (CRO)

  5. Slide 5: Team with a strong track record of clinical development and shareholder value creation

    Slide 5: Team with a strong track record of clinical development and shareholder value creation

    Team with a strong track record of clinical development and shareholder value creation PAWEL PRZEWIEZLIKOWSKI, MSc, MBA KRZYSZTOF BRZOZKA, Ph.D., MBA HENDRIK NOGAI, M.D. KAMIL SITARZ, Ph.D., MBA VATNAK VAT-HO, MBA CEO and Founder CSO CMO COO CBO PETER LITTLEWOOD, MSc MARTIN SWARBRICK, Ph.D. MATEUSZ

  6. Slide 6: Broad pipeline addressing emerging targets in oncology

    Slide 6: Broad pipeline addressing emerging targets in oncology

    Broad pipeline addressing emerging targets in oncology 6

  7. Slide 7: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    Slide 7: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

  8. Slide 8: RVU120 is a CDK8/19 inhibitor currently in clinical development

    Slide 8: RVU120 is a CDK8/19 inhibitor currently in clinical development

    RVU120 is a CDK8/19 inhibitor currently in clinical development to address unmet medical need in hematologic and solid tumors • First-in-class • High selectivity • Easy to formulate • High potency • Low risk of DDI • Orally available RVU120 is highly selective for CDK8/19 IC50 [nM] CDK8/CyclinC CDK1

  9. Slide 9: RVU120: Potential across a broad range of cancers

    Slide 9: RVU120: Potential across a broad range of cancers

    RVU120: Potential across a broad range of cancers Blood Cancers & Disorders Solid tumors AML Neuroendocrine Low-risk MDS Breast High-risk MDS MDS/MPN overlap syndrome Sarcoma Myelofibrosis (MF) HCC NHL Colorectal Diamond-Blackfan Anemia Prostate • Signs of clinical activity in AML/HR-MDS • Preclinic

  10. Slide 10: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    Slide 10: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML) Preclinical Evidence: AML AML • Most common, highly aggressive CD34+ AML patient-derived xenografts: type of acute leukemia in adults Complete regression Hematologic recovery • Poor outcomes in most patients1 (peripheral blood) (bone mar

  11. Slide 11: DNMT3A and NPM1 are candidates for patient selection markers in AML

    Slide 11: DNMT3A and NPM1 are candidates for patient selection markers in AML

    DNMT3A and NPM1 are candidates for patient selection markers in AML DNMT3A/NPM1 mutated AML is dependent on dysregulation of HOX genes Loss of viability with RVU120 treatment • Low nM activity on CDK8/19: RVU120 reduces the viability of AML PDCs, in particular those bearing recurrent DNMT3A and NPM1

  12. Slide 12: Combination potential with venetoclax was shown in preclinical models

    Slide 12: Combination potential with venetoclax was shown in preclinical models

    Combination potential with venetoclax was shown in preclinical models Synergistic activity was demonstrated in venetoclax sensitive Synergy is driven by regulation of MCL-1: and venetoclax resistant models: Venetoclax sensitive RVU120 RVU120 cell line MCL-1 BCL-2 BCL-XL 4000 T u m o r v o lu m e , d

  13. Slide 13: RVU120 validated preclinically as a drug candidate in Myelofibrosis (MF)

    Slide 13: RVU120 validated preclinically as a drug candidate in Myelofibrosis (MF)

    RVU120 validated preclinically as a drug candidate in Myelofibrosis (MF) Mechanism of RVU120 activity in MF Opportunity in Myelofibrosis • Growing market with many patients undiagnosed or not treated due to lack of treatment options • Long durations of therapy and unmet medical need, for example in

  14. Slide 14: RVU120: Phase I AML/MDS Study

    Slide 14: RVU120: Phase I AML/MDS Study

    RVU120: Phase I AML/MDS Study Recruitment in Phase I ongoing 5 SITES IN US STUDY POPULATION: TREATMENT: Three-week cycle: Single oral dose of RVU120 every • Patients with other day for a total of 7 doses/cycle followed by relapsed/refractory AML or one week off high risk MDS • No upfront patient str

  15. Slide 15: RVU120 has a favorable safety profile at doses tested to date

    Slide 15: RVU120 has a favorable safety profile at doses tested to date

    RVU120 has a favorable safety profile at doses tested to date RVU120 (10-135 mg) Most common* Treatment Emergent RVU120 was well tolerated Adverse Events (TEAE) Any grade n of pts (%) Grade 3-5 n of pts (%) at doses between 10 and 135 mg Nausea 19 (61%) 0 Vomiting 10 (32%) 1 (3%) • No DLTs and no st

  16. Slide 16: Clinical Update: 11 of 24 evaluable patients showed clinical benefit

    Slide 16: Clinical Update: 11 of 24 evaluable patients showed clinical benefit

    Clinical Update: 11 of 24 evaluable patients showed clinical benefit • A total of 29 patients have been treated • Median age 71 years • Patients relapsed or were refractory to a median of 3 prior lines of therapy Signs of clinical benefit were observed in 11 patients • In total, seven patients exper

  17. Slide 17: RVU120 differentiation on hematopoietic cells: evidence of increased erythroid differentiation

    Slide 17: RVU120 differentiation on hematopoietic cells: evidence of increased erythroid differentiation

    RVU120 differentiation on hematopoietic cells: 6 patients with evidence of increased erythroid differentiation Pt 106-004 Erythroid and Platelet response Pt 106-004 Enhanced Erythroid differentiation 200 150 150 100 52 [x 1 0 / L ]H g b [g / d l] 1 1 .0 1 1 .4 50 22 PLTS 10 9 .6 10 9 5 1 0 1 1 1 1 1

  18. Slide 18: pSTAT5 inhibition correlates with drug exposure in RVU120 studies

    Slide 18: pSTAT5 inhibition correlates with drug exposure in RVU120 studies

    In patients treated in both ongoing RVU120 studies, pSTAT5 inhibition correlates with drug exposure 0 Relevant pharmacodynamic effects were observed in both trials -20 % change pSTAT5 • STAT5 is a direct target of CDK8 vs baseline -40 • A decreasing level of pSTAT5 -60 indicates increasing target en

  19. Slide 19: RVU120 Market Potential in Hematological Malignancies

    Slide 19: RVU120 Market Potential in Hematological Malignancies

    RVU120 Market Potential in Hematological Malignancies AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME) MF (MYELOFIBROSIS) • The most common, highly • Disease leading to bone marrow • MF is a bone marrow disease aggressive type damage, classified as cancer characterized by JAK mutations; o

  20. Slide 20: RVU120 in Solid Tumors

    Slide 20: RVU120 in Solid Tumors

    RVU120 in Solid Tumors Broad potential in solid tumors with strong preclinical evidence in TNBC Evidence in TNBC Solid • Preclinical evidence of activity RVU120 tested in subcutaneous xenograft of a TNBC cell line. Tumors across various solid tumors Tumor volume kinetics Body weight kinetics • Poten

  21. Slide 21: RVU120: Phase I Solid Tumor Study

    Slide 21: RVU120: Phase I Solid Tumor Study

    RVU120: Phase I Solid Tumor Study Recruitment in Phase I ongoing STUDY POPULATION: TREATMENT: Three week cycle: Single oral dose of RVU120 every • Patients with r/r solid other day for a total of 7 doses/cycle followed by 2 SITES IN POLAND + 3 SITES IN SPAIN tumors progressing after at one week off

  22. Slide 22: Initial RVU120 Phase I data in solid tumors

    Slide 22: Initial RVU120 Phase I data in solid tumors

    Initial RVU120 Phase I data in solid tumors Disease stabilization in 4 out of 11 evaluable patients Treatment-emergent AEs: • The Phase I part included a heavily pretreated, unselected all- comer population. • 17 patients were treated at doses between 75 mg and 175 mg. • Disease stabilization was ac

  23. Slide 23: Ryvu is committed to execute a broad Clinical Development Plan for RVU120

    Slide 23: Ryvu is committed to execute a broad Clinical Development Plan for RVU120

    Ryvu is committed to execute a broad Clinical Development Plan for RVU120 HEMATOLOGY CANCERS 2023 2024 2025 2026 2027 2028 US Patient I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV I Opportunity II III IV 1 Fast-to-market strategy: Ph I RVU120 monotherapy 3,400+ Pivotal Ph I

  24. Slide 24: RVU120: Acceleration of value creation in 2022 and beyond

    Slide 24: RVU120: Acceleration of value creation in 2022 and beyond

    RVU120: Acceleration of value creation in 2022 and beyond Leading with Science Clinical Trials Execution strategy Financial strength • Wholly owned, • Demonstrating proof-of- • Defined pathway to the • Cost-efficient first-in-class, selective oral concept, single-agent activity registration of RVU12

  25. Slide 25: SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

    Slide 25: SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

    SEL24 (MEN1703): First-in-Class PIM/FLT3 Inhibitor in AML

  26. Slide 26: SEL24 (MEN1703) – Summary

    Slide 26: SEL24 (MEN1703) – Summary

    SEL24 (MEN1703) – Summary Project licensed to Menarini Group, currently in Phase II in AML Partnership agreement Proven safety Future with Menarini Group (2017) and therapeutic efficacy directions • PLN 20.3m upfront payment • Phase II partial clinical data (EHA2022) • Potential future milestones •

  27. Slide 27: SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients

    Slide 27: SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients

    SEL24 (MEN1703) showed single-agent efficacy in R/R AML patients, in particular in the IDH+ population, in the Dose Escalation/Cohort Expansion study Efficacy • Objective responses have been reported in 4 out of 48 patients (8%) across DE and CE phases, with 3 out of 4 responders harboring IDH mutat

  28. Slide 28: Summary of recent progress in SEL24

    Slide 28: Summary of recent progress in SEL24

    Summary of recent progress in SEL24 2021 2022 2023 06/2021 / ASCO, EHA 06/2022 / ASCO, EHA • Manageable safety profile at the recommended dose Poster • Preliminary single agent efficacy in relapsed/refractory AML, • 25 patients enrolled in the IDHm cohort particularly in patients with IDH mutant dis

  29. Slide 29: Small Molecule Platform with Focus on Synthetic Lethality

    Slide 29: Small Molecule Platform with Focus on Synthetic Lethality

    Small Molecule Platform with Focus on Synthetic Lethality

  30. Slide 30: Integrated Discovery Engine at Ryvu

    Slide 30: Integrated Discovery Engine at Ryvu

    Integrated Discovery Engine at Ryvu TARGET IDENTIFICATION AND VALIDATION DRUG DISCOVERY RESEARCH PIPELINE  Discovery of novel synthetic lethal target  Integrated, multidisciplinary processes:  Broad portfolio of synthetic lethal and pairs and actionable oncogenic drivers rapid lead identification

  31. Slide 31: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Slide 31: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Ryvu’s Target Discovery Platform is focused on identification of novel synthetic lethal pairs and oncogenic drivers INPUT DATA TARGET DISCOVERY PLATFORM PLATFORM OUTPUT CRISPR / shRNA Screens Novel Synthetic Lethalities Novel and Proprietary SL Targets Target #1 • Single-most synthetic lethal target

  32. Slide 32: Experimental target discovery platform – three approaches

    Slide 32: Experimental target discovery platform – three approaches

    Experimental target discovery platform – three approaches Experimental CRISPR-based target discovery platforms with the use of: Isogenic cell line pair Isogenic primary cells Patient-derived material Normal conditions Stress conditions MUT1 MUT2 MUT3 MUT4 Cellular stress in CRISPR screens tumor micr

  33. Slide 33: PRMT5 MTA-cooperative inhibitors

    Slide 33: PRMT5 MTA-cooperative inhibitors

    PRMT5 MTA-cooperative inhibitors PRMT5 SL INHIBITOR PROGRAM IN RYVU RYVU HAS SL PRMT5 INHIBITORS WITH THE BEST-IN-CLASS POTENTIAL PRMT5 MTA-cooperative inhibitors KEY RATIONALE exert synthetic lethal phenotype in MTAP deleted cells MECHANISM MRTX MTA-cooperative inhibitors 1719 RVU4 RVU5 RVU6 OF ACT

  34. Slide 34: Small molecule inhibitors of WRN

    Slide 34: Small molecule inhibitors of WRN

    Small molecule inhibitors of WRN WRN INHIBITORS OF ATPase ACTIVITY SELECTIVELY TARGETING TUMORS WRN INHIBITOR PROGRAM AT RYVU WITH MICROSATELLITE INSTABILITY Synthetic lethality of WRN 1 KEY RATIONALE Helicase function validated with microsatellite instability (MSI-high) in vitro as critical require

  35. Slide 35: BioNTech and Ryvu: Global Collaboration on Immune Modulation Small Molecules

    Slide 35: BioNTech and Ryvu: Global Collaboration on Immune Modulation Small Molecules

    BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates Largest-ever Ryvu deal November 2022 • Multi-target discovery collaboration on small molecule programs in immune modulation • STING agonist license as a monotherapy and in combinations Pa

  36. Slide 36: Exelixis and Ryvu: Exclusive License Agreement for STING Agonist-Based Therapies

    Slide 36: Exelixis and Ryvu: Exclusive License Agreement for STING Agonist-Based Therapies

    Exelixis and Ryvu: Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies July 2022 • Building STING-based antibody drug conjugates (ADCs) • Leveraging Ryvu’s STING agonist portfolio and Exelixis’s ADC technology Partnership Key Financial Terms • Exclusive license

  37. Slide 37: Corporate Progress

    Slide 37: Corporate Progress

    RYYU THERAPEUTICS Corporate Progress

  38. Slide 38: Full-Year Financial Results: Q1 YTD 2023

    Slide 38: Full-Year Financial Results: Q1 YTD 2023

    Full-Year Financial Results: Q1 YTD 2023 Q1YTD Q1YTD $ million 2022* 2022* 2023* Cash position # of employees Revenues, incl.: 15.8 1.7 4.3 May 11, 2023 Partnering 8.7 0.0 2.9 Grants 6.6 1.6 1.3 $71.8M Total Costs**, incl.: 26.4 6.1 7.5 Clinical Pipeline 6.4 1.6 1.8 Available EIB Venture Debt Early

  39. Slide 39: EUR 22m venture debt obtained from the European Investment Bank

    Slide 39: EUR 22m venture debt obtained from the European Investment Bank

    EUR 22m venture debt obtained from the European Investment Bank Long-term financing for innovative growth companies: Instrument structure adapted to the business model Long-term financing repaid through bullet repayment, and remuneration independent of interest rates, partially secured by the Compan

  40. Slide 40: Business Pipeline: 2023-2024 Key Goals and Financing

    Slide 40: Business Pipeline: 2023-2024 Key Goals and Financing

    Ryvu’s Vision: From 2025, Ryvu will improve the lives of cancer patients worldwide 2023-2024 KEY GOALS AND FINANCING  Research funding from existing R&D collaborations  RVU120 broad development  Milestones from existing R&D collaborations  New grant funding (including potential fast-to-market st

  41. Slide 41: Ryvu Equity Summary

    Slide 41: Ryvu Equity Summary

    Ryvu Equity Summary IPO on WSE Nov 2014 Top Holders3 Corporate Split: Selvita and Ryvu Oct 2019 1 Paweł Przewięźlikowski 18% 2 Allianz OFE 9.2% Ticker: WSE RVU 3 BioNTech SE 8.3% 52-Week Range1 PLN 30.40 – 65.80 4 Allianz TFI 8.3% Average Daily Volume (YTD) 1 7,982 5 Nationale-Nederlanden OFE 8.2% 6

  42. Slide 42: Contact Data

    Slide 42: Contact Data

    CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com 42

Source: Internet Archive copy of ryvu.com

More decks from Ryvu Therapeutics SA

All 21 Ryvu Therapeutics SA decks